berberine has been researched along with Hyperlipemia in 38 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine, extracted from Coptis Root and Phellodendron Chinese, has been frequently used for the adjuvant treatment of type 2 diabetes mellitus, hyperlipidemia, and hypertension in China." | 8.91 | Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. ( Dong, F; Fan, J; Lan, J; Sun, G; Yan, Z; Zhao, Y; Zheng, W, 2015) |
| "Berberine can counteract HFD-elicited hyperhomocysteinemia and hyperlipidemia partially via upregulating LDLR and apoE mRNA levels and suppressing HMGR gene expression." | 7.78 | The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. ( Bian, H; Chang, XX; Gao, X; Xia, MF; Xu, Q; Yan, HM; Zhu, TF, 2012) |
| "Hyperlipidemia is one of the principal factors underlying numerous metabolic diseases, including diabetes and obesity." | 5.43 | Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. ( Ma, S; She, L; Tian, X; Yan, S; Yang, W; Yu, K; Zhang, X, 2016) |
| "A double-blind, randomized, placebo-controlled, dose ranging study was carried out that compared three doses of berberine ursodeoxycholate (BUDCA) to placebo in a cohort of subjects with a history of hypercholesterolemia and serum LDL cholesterol levels above 2." | 5.34 | Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. ( Bai, R; Di Bisceglie, AM; Lavin, P; Liu, L; Watts, GF; Yu, M, 2020) |
| "Berberine, extracted from Coptis Root and Phellodendron Chinese, has been frequently used for the adjuvant treatment of type 2 diabetes mellitus, hyperlipidemia, and hypertension in China." | 4.91 | Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. ( Dong, F; Fan, J; Lan, J; Sun, G; Yan, Z; Zhao, Y; Zheng, W, 2015) |
| "Berberine can counteract HFD-elicited hyperhomocysteinemia and hyperlipidemia partially via upregulating LDLR and apoE mRNA levels and suppressing HMGR gene expression." | 3.78 | The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. ( Bian, H; Chang, XX; Gao, X; Xia, MF; Xu, Q; Yan, HM; Zhu, TF, 2012) |
| "The aim of this paper was to determine the activity of a natural nutraceuticals combination (AP=Berberine+Red Yeast Rice) on dyslipidemia which frequently persists after life style changes in patients on hormone-therapy following breast cancer (HT-BC)." | 3.78 | Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer. ( Benvenuti, C; Pezzana, A; Quirico, E; Zanardi, M, 2012) |
| "Berberine did not lower testosterone but instead may increase testosterone in men, suggesting sex-specific effects of berberine." | 3.01 | Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial. ( Chan, YH; Ho, WK; Ip, DKM; Leung, JYY; Schooling, CM; Tse, HF; Vackova, D; Yeung, WF; Zhao, J; Zhao, JV, 2021) |
| "Totally 102 mild hyperlipemia patients were recruited." | 2.82 | [Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia]. ( Ge, H; Peng, LY; Wang, L; Wei, GH, 2016) |
| "To systematically evaluate the efficacy and safety of berberine for the treatment of hyperlipidemia, six electronic literature databases including SinoMed, CNKI, WanFang Data, PubMed, Embase and The Cochrane Library were searched to collect clinical randomized controlled trials (RCTs) of berberine alone or combined with statins for the treatment of hyperlipidemia from the inception to 8 March 2018." | 2.61 | Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. ( Feng, R; Ji, ZC; Jin, XY; Li, XM; Yang, FW; Zhang, BL; Zhang, JH; Zhang, LS; Zhang, MY; Zhao, MY, 2019) |
| " It is necessary to improve the oral bioavailability of BBR before it can be used in many clinical applications." | 2.53 | Research progress on berberine with a special focus on its oral bioavailability. ( Liu, CS; Long, XY; Zhang, YF; Zheng, YR, 2016) |
| "However, the efficacy of berberine in treating hyperlipidemia should be further evaluated by more randomized controlled trials in a larger population of patients." | 2.49 | The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. ( Dong, H; Lu, F; Zhao, L; Zhao, Y, 2013) |
| " However, as the two agents have very different chemical structure and bioavailability in oral route, the goal of this study is to learn their characteristics in treating metabolic disorders." | 1.91 | Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. ( Gao, TL; Guo, HH; Han, YX; Jiang, JD; Luo, ZG; Shen, HR; Wang, LL; Zhang, HJ; Zhang, JL, 2023) |
| "Berberine (BBR) is an effective cholesterol-lowering drug." | 1.72 | The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression. ( Wang, QC; Wu, C; Xu, W; Yang, YN; Yu, J; Zhang, H, 2022) |
| "Berberine (BBR) is a natural lipid lowering drug that reduces plasma LDL-cholesterol (LDL-C), total cholesterol (TC) and TG in hyperlipidemic patients and in mice by mechanisms involving upregulation of hepatic LDL receptor (LDLR)." | 1.51 | Berberine decreases plasma triglyceride levels and upregulates hepatic TRIB1 in LDLR wild type mice and in LDLR deficient mice. ( Liu, J; Singh, AB, 2019) |
| "The rat model of hyperlipidemia was established by providing high-fat-diet (HFD) for 4 weeks." | 1.46 | Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats. ( Liu, L; Ni, H; Ren, F; Ren, J; Shen, T; Wei, H; Wei, J; Xu, S; Zhou, X, 2017) |
| "Hyperlipidemia is a major component of metabolic syndrome, and often predicts cardiovascular diseases." | 1.43 | Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds. ( Ji, G; Li, M; Shu, X; Xu, H; Yang, L; Zhang, C; Zhang, L, 2016) |
| "Hyperlipidemia is one of the principal factors underlying numerous metabolic diseases, including diabetes and obesity." | 1.43 | Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. ( Ma, S; She, L; Tian, X; Yan, S; Yang, W; Yu, K; Zhang, X, 2016) |
| "Hdber is effective in the treatment of hyperlipidemia in rats." | 1.42 | Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia. ( Chen, G; Dong, H; Huang, ZY; Liu, DL; Lu, FE; Luo, YH; Wang, KF; Xu, LJ; Zou, X, 2015) |
| " However, pharmacokinetic studies showed that berberine was poorly absorbed into the body so the levels of berberine in the blood and target tissues were far below the effective concentrations revealed." | 1.42 | A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine. ( Aa, J; Cao, B; Gu, S; Hylemon, PB; Li, Y; Liu, L; Paletta, JL; Radlon, JM; Ridlon, JM; Sun, R; Tang, Y; Wang, G; Wu, X; Wu, XL; Zha, W; Zhao, C; Zhou, H, 2015) |
| "The hyperlipidemia zebrafish model was successfully established by feeding with 4% cholesterol for 20 days." | 1.42 | [Efficient and rapid liquid reduction animal model]. ( Chen, B; Han, B; Han, YL; Kou, SM; Li, XG; Peng, YZ; Wang, Y; Ye, XL, 2015) |
| "Berberine is an isoquinoline alkaloid present in several plant species, including Coptis sp." | 1.40 | Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications. ( Chen, C; Fichna, J; Li, Y; Storr, M; Yu, Z, 2014) |
| "Similar effects from lovastatin on lipidemia were observed except the Ber effect on CPT I A gene expression." | 1.37 | [Study on effect of berberine on modulating lipid and CPT I A gene expression]. ( Shi, L; Wang, H; Yin, H; Zhou, Q, 2011) |
| "In order to enhance oral bioavailability of berberine (BBR) for its cholesterol-lowering efficacy in vivo, a series of ester or ether prodrugs of berberrubine (M1), which is an active metabolite of BBR after first-pass metabolism, were designed, semi-synthesized, and evaluated." | 1.36 | Design, synthesis, and cholesterol-lowering efficacy for prodrugs of berberrubine. ( Deng, HB; Jiang, JD; Kong, WJ; Li, Y; Li, YH; Ren, G; Song, DQ; Wang, YM; Wang, YX; Yang, P; You, XF, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.63) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.26) | 29.6817 |
| 2010's | 28 (73.68) | 24.3611 |
| 2020's | 7 (18.42) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, C | 2 |
| Zhao, Y | 3 |
| Zhang, Y | 1 |
| Yang, Y | 3 |
| Su, W | 1 |
| Sun, L | 1 |
| Zhang, F | 1 |
| Yu, J | 2 |
| Wang, Y | 3 |
| Guo, P | 1 |
| Zhu, B | 1 |
| Wu, S | 1 |
| Chen, Y | 2 |
| Li, K | 1 |
| Zhao, H | 1 |
| Hao, Z | 1 |
| Gao, M | 1 |
| Zhao, D | 1 |
| Yang, YN | 1 |
| Wang, QC | 1 |
| Xu, W | 1 |
| Zhang, H | 1 |
| Guo, HH | 1 |
| Shen, HR | 1 |
| Wang, LL | 1 |
| Luo, ZG | 1 |
| Zhang, JL | 1 |
| Zhang, HJ | 1 |
| Gao, TL | 1 |
| Han, YX | 1 |
| Jiang, JD | 5 |
| Singh, AB | 1 |
| Liu, J | 1 |
| Li, DD | 2 |
| Yu, P | 1 |
| Xiao, W | 1 |
| Wang, ZZ | 1 |
| Zhao, LG | 1 |
| Di Bisceglie, AM | 1 |
| Watts, GF | 1 |
| Lavin, P | 1 |
| Yu, M | 1 |
| Bai, R | 1 |
| Liu, L | 3 |
| Zhao, JV | 1 |
| Yeung, WF | 1 |
| Chan, YH | 1 |
| Vackova, D | 1 |
| Leung, JYY | 1 |
| Ip, DKM | 1 |
| Zhao, J | 1 |
| Ho, WK | 1 |
| Tse, HF | 1 |
| Schooling, CM | 1 |
| Koppen, LM | 1 |
| Whitaker, A | 1 |
| Rosene, A | 1 |
| Beckett, RD | 1 |
| Zhou, X | 1 |
| Ren, F | 1 |
| Wei, H | 1 |
| Shen, T | 1 |
| Xu, S | 1 |
| Wei, J | 1 |
| Ren, J | 1 |
| Ni, H | 1 |
| Feng, J | 1 |
| Li, H | 1 |
| Zhao, W | 2 |
| Dang, H | 1 |
| Wang, R | 1 |
| Luo, K | 1 |
| Guo, H | 1 |
| Xing, W | 1 |
| Cheng, J | 1 |
| Song, W | 1 |
| Sun, Y | 1 |
| Xie, L | 1 |
| Zhu, TL | 1 |
| Yang, B | 1 |
| Guo, YS | 1 |
| Ji, YS | 1 |
| Li, XY | 2 |
| Zhang, LS | 1 |
| Zhang, JH | 1 |
| Feng, R | 2 |
| Jin, XY | 1 |
| Yang, FW | 1 |
| Ji, ZC | 1 |
| Zhao, MY | 1 |
| Zhang, MY | 1 |
| Zhang, BL | 1 |
| Li, XM | 1 |
| Dong, H | 3 |
| Zhao, L | 1 |
| Lu, F | 1 |
| Yao, J | 1 |
| Kong, W | 1 |
| Jiang, J | 1 |
| Liu, DL | 1 |
| Xu, LJ | 2 |
| Chen, G | 1 |
| Huang, ZY | 1 |
| Zou, X | 2 |
| Wang, KF | 2 |
| Luo, YH | 1 |
| Lu, FE | 2 |
| Chen, C | 1 |
| Yu, Z | 1 |
| Li, Y | 3 |
| Fichna, J | 1 |
| Storr, M | 1 |
| Li, Z | 1 |
| Kong, WJ | 3 |
| Gu, S | 1 |
| Cao, B | 1 |
| Sun, R | 1 |
| Tang, Y | 1 |
| Paletta, JL | 1 |
| Wu, X | 1 |
| Wu, XL | 1 |
| Zha, W | 1 |
| Zhao, C | 1 |
| Ridlon, JM | 1 |
| Radlon, JM | 1 |
| Hylemon, PB | 1 |
| Zhou, H | 1 |
| Aa, J | 1 |
| Wang, G | 1 |
| Lan, J | 1 |
| Dong, F | 1 |
| Yan, Z | 1 |
| Zheng, W | 1 |
| Fan, J | 1 |
| Sun, G | 1 |
| Cicero, AF | 1 |
| Rosticci, M | 1 |
| Parini, A | 1 |
| Morbini, M | 1 |
| Urso, R | 1 |
| Grandi, E | 1 |
| Borghi, C | 1 |
| Jiang, SJ | 1 |
| Li, JB | 1 |
| Yi, P | 1 |
| Zhao, ZX | 1 |
| Huang, M | 1 |
| He, CY | 1 |
| Ma, C | 1 |
| Luo, SH | 1 |
| Fu, J | 1 |
| Wen, BY | 1 |
| Ren, L | 1 |
| Shou, JW | 1 |
| Guo, F | 1 |
| Gao, X | 2 |
| Liu, CS | 1 |
| Zheng, YR | 1 |
| Zhang, YF | 1 |
| Long, XY | 1 |
| Han, B | 1 |
| Kou, SM | 1 |
| Chen, B | 1 |
| Peng, YZ | 1 |
| Han, YL | 1 |
| Ye, XL | 1 |
| Li, XG | 1 |
| Yu, H | 1 |
| Li, C | 1 |
| Yang, J | 1 |
| Zhang, T | 1 |
| Zhou, Q | 2 |
| Wang, L | 1 |
| Peng, LY | 1 |
| Wei, GH | 1 |
| Ge, H | 1 |
| Li, M | 1 |
| Shu, X | 1 |
| Xu, H | 1 |
| Zhang, C | 1 |
| Yang, L | 1 |
| Zhang, L | 2 |
| Ji, G | 1 |
| Yang, W | 1 |
| She, L | 1 |
| Yu, K | 1 |
| Yan, S | 1 |
| Zhang, X | 2 |
| Tian, X | 1 |
| Ma, S | 1 |
| Zhou, JY | 2 |
| Zhou, SW | 2 |
| Zhang, KB | 1 |
| Tang, JL | 1 |
| Guang, LX | 1 |
| Ying, Y | 1 |
| Xu, Y | 1 |
| Li, YH | 1 |
| Yang, P | 1 |
| You, XF | 1 |
| Ren, G | 1 |
| Deng, HB | 1 |
| Wang, YM | 1 |
| Wang, YX | 1 |
| Song, DQ | 1 |
| Wang, H | 1 |
| Shi, L | 1 |
| Yin, H | 1 |
| Hu, Y | 1 |
| Ehli, EA | 1 |
| Kittelsrud, J | 1 |
| Ronan, PJ | 1 |
| Munger, K | 1 |
| Downey, T | 1 |
| Bohlen, K | 1 |
| Callahan, L | 1 |
| Munson, V | 1 |
| Jahnke, M | 1 |
| Marshall, LL | 1 |
| Nelson, K | 1 |
| Huizenga, P | 1 |
| Hansen, R | 1 |
| Soundy, TJ | 1 |
| Davies, GE | 1 |
| Chang, XX | 1 |
| Yan, HM | 1 |
| Xu, Q | 1 |
| Xia, MF | 1 |
| Bian, H | 1 |
| Zhu, TF | 1 |
| Zanardi, M | 1 |
| Quirico, E | 1 |
| Benvenuti, C | 1 |
| Pezzana, A | 1 |
| Xue, R | 1 |
| Zhou, ZX | 1 |
| Umeda, M | 1 |
| Amagaya, S | 1 |
| Ogihara, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With Hypercholesterolemia[NCT03381287] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2018-04-13 | Completed | ||
| Effect of Berberine on Cardiovascular Disease Risk Factors: a Mechanistic Randomized Controlled Trial[NCT03770325] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2019-04-01 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders[NCT02983188] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2018-04-25 | Completed | ||
| The Effect of Berberine on the Secretion of Incretin in Normal Man[NCT05947370] | Early Phase 1 | 16 participants (Actual) | Interventional | 2022-10-12 | Completed | ||
| A Phase I, Randomized, Crossover, Double-blind, Pharmacokinetic Study of Berberine Released From Cyclodextrin in Healthy Volunteers[NCT04918667] | Phase 1 | 16 participants (Anticipated) | Interventional | 2024-09-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 28
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg BID | 1.770 | 3370 |
| HTD1801 250 mg BID | 0.676 | 962 |
| HTD1801 500 mg BID | 1.510 | 1900 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 1
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg | 0.865 | 2900 |
| HTD1801 250 mg | 0.390 | 923 |
| HTD1801 500 mg | 0.441 | 1900 |
TEAEs are defined as any AEs that commenced on or after exposure to study drug or any pre-existing AE that worsened in either intensity or frequency after exposure to study drug. (NCT03381287)
Timeframe: 4 weeks
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| TEAE | Serious TEAE | Severe TEAE | Drug-related TEAEs | TEAEs leading to treatment interrupted or discontinued | |
| HTD1801 1000 mg BID | 11 | 1 | 0 | 6 | 1 |
| HTD1801 250 mg BID | 10 | 0 | 0 | 2 | 0 |
| HTD1801 500 mg BID | 8 | 0 | 0 | 7 | 0 |
| Placebo | 8 | 0 | 1 | 4 | 0 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -32.192 | -34.382 |
| HTD1801 250 mg BID | -38.672 | -46.458 |
| HTD1801 500 mg BID | -41.295 | 47.246 |
| Placebo | -41.743 | -33.153 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -13.034 | -21.916 |
| HTD1801 250 mg BID | -19.527 | -11.239 |
| HTD1801 500 mg BID | 222.4113 | 242.570 |
| Placebo | -4.975 | 10.582 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -9.296 | -9.767 |
| HTD1801 250 mg BID | -3.390 | -7.674 |
| HTD1801 500 mg BID | -1.1550 | 0.372 |
| Placebo | 3.624 | -3.585 |
(NCT03381287)
Timeframe: Baseline, Day 14, Day 28
| Intervention | percentage change from baseline (Mean) | |
|---|---|---|
| Percent Change from Baseline to Day 14 | Percent Change from Baseline to Day 28 | |
| HTD1801 1000 mg BID | -2.240 | 6.256 |
| HTD1801 250 mg BID | -5.788 | 7.684 |
| HTD1801 500 mg BID | 12.798 | 25.882 |
| Placebo | 1.724 | 36.778 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 28
| Intervention | hours (Mean) |
|---|---|
| Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg BID | 7.53 |
| HTD1801 500 mg BID | 7.60 |
(NCT03381287)
Timeframe: 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 1
| Intervention | hours (Mean) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg | 7.79 | 5.24 |
| HTD1801 250 mg | 9.04 | 2.79 |
| HTD1801 500 mg | 10.60 | 8.43 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 28
| Intervention | hours (Median) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg BID | 4.0 | 3.0 |
| HTD1801 250 mg BID | 4.0 | 3.0 |
| HTD1801 500 mg BID | 4.0 | 4.0 |
(NCT03381287)
Timeframe: 0. 0.25, 0.5, 1, 2, 3, 4, 8, 12 and 24 hours on Day 1
| Intervention | hours (Median) | |
|---|---|---|
| Berberine (BBR) | Ursodeoxycholic Acid (UDCA) | |
| HTD1801 1000 mg | 4.0 | 4.0 |
| HTD1801 250 mg | 3.5 | 2.0 |
| HTD1801 500 mg | 4.0 | 3.0 |
7 reviews available for berberine and Hyperlipemia
| Article | Year |
|---|---|
Berberine: A Promising Natural Isoquinoline Alkaloid for the Development of Hypolipidemic Drugs.
Topics: Berberine; Humans; Hyperlipidemias; Hypolipidemic Agents; Molecular Structure; Structure-Activity Re | 2020 |
Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic Review.
Topics: Berberine; Biological Products; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Fema | 2017 |
Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
Topics: Berberine; Cholesterol; Databases, Bibliographic; Drug Therapy, Combination; Humans; Hydroxymethylgl | 2019 |
The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials.
Topics: Adult; Berberine; Cholesterol; Humans; Hyperlipidemias; Lipids; Lipoproteins, HDL; Lipoproteins, LDL | 2013 |
Learning from berberine: Treating chronic diseases through multiple targets.
Topics: Berberine; China; Chronic Disease; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hyperlipidemia | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Topics: Antihypertensive Agents; Berberine; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension | 2015 |
Research progress on berberine with a special focus on its oral bioavailability.
Topics: Administration, Oral; Animals; Berberine; Biological Availability; Diabetes Mellitus; Humans; Hyperl | 2016 |
5 trials available for berberine and Hyperlipemia
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia.
Topics: Adult; Aged; Berberine; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; D | 2020 |
Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial.
Topics: Adult; Anticholesteremic Agents; Berberine; Blood Pressure; Body Mass Index; Cholesterol; Cholestero | 2021 |
Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial.
Topics: Adult; Aged; Berberine; Chlorogenic Acid; Cross-Over Studies; Dietary Supplements; Double-Blind Meth | 2015 |
[Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia].
Topics: Berberine; Blood Glucose; Body Mass Index; Capsules; Humans; Hyperlipidemias; Lipids | 2016 |
Lipid-lowering effect of berberine in human subjects and rats.
Topics: Adult; Animals; Berberine; Calcitriol; Cholesterol; Coptis; Drugs, Chinese Herbal; Female; Humans; H | 2012 |
26 other studies available for berberine and Hyperlipemia
| Article | Year |
|---|---|
Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decreasing efficacy in patients.
Topics: Animals; Bacteria; Berberine; Cholesterol; Gastrointestinal Microbiome; Humans; Hyperlipidemias; Mic | 2022 |
Integrated lipidomics and network pharmacology analysis to reveal the mechanisms of berberine in the treatment of hyperlipidemia.
Topics: Animals; Berberine; Cricetinae; Humans; Hyperlipidemias; Lipidomics; Lipids; Network Pharmacology | 2022 |
The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression.
Topics: Animals; Bacteria; Berberine; Butyrates; Cholesterol; Diet, High-Fat; Hypercholesterolemia; Hyperlip | 2022 |
Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases.
Topics: Animals; Berberine; Cricetinae; Hyperlipidemias; Lipids; Metformin; Mice; Obesity | 2023 |
Berberine decreases plasma triglyceride levels and upregulates hepatic TRIB1 in LDLR wild type mice and in LDLR deficient mice.
Topics: Acetyl-CoA Carboxylase; Animals; Berberine; Cholesterol, LDL; Humans; Hyperlipidemias; Intracellular | 2019 |
Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats.
Topics: Administration, Oral; Animals; Apolipoprotein B-48; Berberine; Body Weight; Cholesterol, LDL; Coptis | 2017 |
Biological-Profiling-Based Systematic Analysis of Rhizoma Coptidis from Different Growing Regions and Its Anticholesterol Biosynthesis Activity on HepG2 Cells.
Topics: Berberine; Cholesterol; Coptis chinensis; Drugs, Chinese Herbal; Hep G2 Cells; Humans; Hyperlipidemi | 2018 |
[Effects of the Traditional Chinese Medicine berberine on antiatheroscloresis and antioxidant activities in hyperlipoidemic model rats].
Topics: Animals; Antioxidants; Atherosclerosis; Berberine; Cholesterol; Drugs, Chinese Herbal; Glutathione P | 2017 |
Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins B; Berberine; Hydroxymethylglutaryl CoA Reductases; Hyp | 2015 |
Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications.
Topics: Animals; Anti-Inflammatory Agents; Antidiarrheals; Antineoplastic Agents; Berberine; Berberis; Cardi | 2014 |
Berberine up-regulates hepatic low-density lipoprotein receptor through Ras-independent but AMP-activated protein kinase-dependent Raf-1 activation.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Cell Line; Humans; Hyperlipidemias; Liver; Male; | 2014 |
A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine.
Topics: Administration, Oral; Animals; Berberine; Body Weight; Cholestanetriol 26-Monooxygenase; Cholesterol | 2015 |
Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.
Topics: Active Transport, Cell Nucleus; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; AM | 2015 |
Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Berberine; Cholesterol; Cholesterol, LDL | 2015 |
[Efficient and rapid liquid reduction animal model].
Topics: Animals; Berberine; Cholesterol; Disease Models, Animal; Drugs, Chinese Herbal; Female; Humans; Hype | 2015 |
Berberine is a potent agonist of peroxisome proliferator activated receptor alpha.
Topics: Animals; Berberine; Carnitine O-Palmitoyltransferase; Hep G2 Cells; Humans; Hyperlipidemias; Hypolip | 2016 |
Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds.
Topics: Animals; Berberine; Body Weight; Diet, High-Fat; Feces; Gastrointestinal Microbiome; Hyperlipidemias | 2016 |
Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model.
Topics: Animals; Berberine; Body Weight; Coptis; Diet, High-Fat; Hyperlipidemias; Hypolipidemic Agents; Insu | 2016 |
Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Chemical and Drug Induced Liver Injury; Diabetes Mel | 2008 |
Design, synthesis, and cholesterol-lowering efficacy for prodrugs of berberrubine.
Topics: Animals; Anticholesteremic Agents; Berberine; Biological Availability; Cholesterol; Hyperlipidemias; | 2010 |
Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver.
Topics: Animals; Antioxidants; Berberine; Coptis; Cyclin T; Cyclin-Dependent Kinase 9; Diabetes Mellitus, Ex | 2011 |
[Study on effect of berberine on modulating lipid and CPT I A gene expression].
Topics: Animals; Berberine; Carnitine O-Palmitoyltransferase; Disease Models, Animal; Drugs, Chinese Herbal; | 2011 |
The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet.
Topics: Animals; Aorta; Apolipoproteins; Atherosclerosis; Berberine; Cholesterol; Cholesterol, LDL; Diet, Hi | 2012 |
Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Berberine; Biological Products; Breast Neopla | 2012 |
Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis.
Topics: Adult; Berberine; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hyperlipidemias; Hypol | 2008 |
Effect of shosaikoto, daisaikoto and sannoshashinto (traditional Japanese and Chinese medicines) on experimental hyperlipidemia in rats.
Topics: Aging; Animals; Berberine; Cholesterol; Cholesterol, Dietary; Drug Combinations; Drugs, Chinese Herb | 1989 |